[{"AccountsPayableCurrent_0_Q2_USD":26125000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":1266038000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":126000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":2512000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":33707000.0,"DepreciationAmortizationAndAccretionNet_2_Q2_USD":15813000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":18855000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":68333000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":33755000.0,"PaymentsForProceedsFromOtherInvestingActivities_2_Q2_USD":300000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-7090000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":859354000.0,"RestrictedCashCurrent_0_Q2_USD":5000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":2249000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":1268424000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-1796000.0,"InvestmentIncomeInterest_2_Q2_USD":8645000.0,"InvestmentIncomeInterest_1_Q2_USD":3165000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":3306000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-1153000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-358144000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-180382000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":5520320000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":99498000.0,"OtherAssetsNoncurrent_0_Q2_USD":20396000.0,"NonoperatingIncomeExpense_2_Q2_USD":49468000.0,"NonoperatingIncomeExpense_1_Q2_USD":20956000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":33231000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":19929000.0,"AccountsReceivableNet_0_Q2_USD":9865000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":1258425000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":9999000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":583281000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":203438000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":103962000.0,"RestrictedInvestmentsNoncurrent_0_Q2_USD":24725000.0,"RestrictedCashNoncurrent_0_Q2_USD":2447000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2_Q2_USD":-257000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":151512000.0,"PaymentsToAcquireRestrictedInvestments_2_Q2_USD":9900000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":1140421000.0,"PaymentsForProceedsFromTenantAllowance_2_Q2_USD":-1991000.0,"OtherOperatingActivitiesCashFlowStatement_2_Q2_USD":4372000.0,"OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_2_Q2_USD":-146000.0,"OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_1_Q2_USD":-72000.0,"OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2_Q2_USD":3049000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_2_Q2_USD":911000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_1_Q2_USD":571000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":229674000.0,"OperatingLeasePayments_2_Q2_USD":18235000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":281618000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":33447000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q2_USD":0.0,"EquitySecuritiesFvNiUnrealizedGainLoss_2_Q2_USD":69643000.0,"EquitySecuritiesFvNi_0_Q2_USD":86310000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-196000.0,"ContractWithCustomerLiabilityRevenueRecognized_2_Q2_USD":31504000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q2_USD":16826000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":281530000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":107587000.0,"ContractWithCustomerLiability_0_Q2_USD":152258000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":33653000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":6402000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":15077000.0,"ProceedsFromIssuanceOfPrivatePlacement_2_Q2_USD":99498000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":45039000.0,"NetIncomeLoss_1_Q2_USD":-179229000.0,"NetIncomeLoss_2_Q2_USD":-361450000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-381491000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-327542000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":742882000.0,"LiabilitiesCurrent_0_Q2_USD":384302000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":3374367000.0,"Liabilities_0_Q2_USD":1974641000.0,"InventoryNet_0_Q2_USD":77418000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":13560000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":26099000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":1901000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":1326000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":36275000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-359549000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-3.18,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.56,"CostsAndExpenses_2_Q2_USD":612455000.0,"CostsAndExpenses_1_Q2_USD":302821000.0,"CommonStockValue_0_Q2_USD":1156000.0,"CommonStockSharesOutstanding_0_Q2_shares":115647000.0,"CommonStockSharesIssued_0_Q2_shares":115647000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":580829000.0,"AssetsCurrent_0_Q2_USD":2160446000.0,"Assets_0_Q2_USD":3374367000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":13625000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-33212000.0,"AccountsReceivableNetCurrent_0_Q2_USD":69115000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-177903000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":88349000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":0.0,"ProfitLoss_2_Q2_USD":-361450000.0,"InventoryWorkInProcess_0_Q2_USD":20686000.0,"InventoryRawMaterials_0_Q2_USD":43515000.0,"InventoryFinishedGoods_0_Q2_USD":13217000.0,"IncreaseDecreaseInInventories_2_Q2_USD":24178000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":2036000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":91873000.0,"ShareBasedCompensation_2_Q2_USD":68333000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":254657000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":127896000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":324567000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":154996000.0,"PreferredStockValue_0_Q2_USD":0.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.01,"OperatingIncomeLoss_2_Q2_USD":-409017000.0,"OperatingIncomeLoss_1_Q2_USD":-198859000.0,"InterestExpense_2_Q2_USD":27248000.0,"InterestExpense_1_Q2_USD":27248000.0,"CommonStockSharesAuthorized_0_Q2_shares":250000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.01,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":211186000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":113830000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":114911000.0,"StockholdersEquity_0_Q2_USD":1399726000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-4088538000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":439126000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":68071000.0,"StockIssuedDuringPeriodValueShareBasedCompensationGross_1_Q2_USD":5301000.0,"Ticker":"ALNY","CIK":"1178670","name":"ALNYLAM PHARMACEUTICALS, INC.","OfficialName":"Alnylam Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"19459816074.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]